Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine

International Journal of Cancer

Volumn 86, Issue 5, 2000, Pages 725-730

  Chang, Edwin Y ^a   Chen, Chien Hung ^b   Ji, Hongxiu ^a   Wang, Tian Li ^a   Hung, Kenneth ^a   Lee, Bruce P ^a   Huang, Alex Y C ^a   Kurman, Robert J ^a   Pardoll, Drew M ^a   Wu, T C ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MITOMYCIN C; TUMOR ANTIGEN; TUMOR CELL VACCINE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; GENETIC ENGINEERING; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; UTERINE CERVIX CARCINOMA; WART VIRUS;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0034063322     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000601)86:5<725::AID-IJC19>3.0.CO;2-K     Document Type: Article

References (30)

1. CHAN, A.D. and MORTON, D.L., Active immunotherapy with allogeneic tumor cell vaccines: Present status. Semin. Oncol., 25, 611-622 (1998).
2. DIALYNAS, D.P., QUAN, Z.S., WALL, K.A., PIERRES, A., QUINTANS, J., LOKEN, M.R., PIERRES, M. and FITCH, F.W., Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: Similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol., 131, 2445-2451 (1983).
3. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D. and MULLIGAN, R.C., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. nat. Acad. Sci. (Wash.), 90, 3539-3543 (1993).
4. HALBERT, C.L., DEMERS, G.W. and GALLOWAY, D.A., The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol., 65, 473-478 (1991).
5. HALBERT, C.L., DEMERS, G.W. and GALLOWAY, D.A., The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J. Virol, 66, 2125-2134 (1992).
6. HUANG, A.Y., GOLUMBEK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D. and LEVITSKY, H., Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science, 264, 961-965 (1994).
7. HUANG, A.Y., BRUCE, A.T., PARDOLL, D.M. and LEVITSKY, H.I., In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity, 4, 349-355 (1996).
8. + T cells in the antitumor immune response. J. exp. Med., 188, 2357-2368 (1998).
9. INABA, K., INABA, M., ROMANI, N., AYA, H., DEGUCHI, M., IKEHARA, S., MURAMATSU, S. and STEINMAN, R.M., Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. exp. Med., 176, 1693-1702 (1992).
10. JAFFEE, E.M. and PARDOLL, D.M., Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods. 12, 143-153 (1997).
11. JAFFEE, E.M., LAZENBY, A., MEURER, J., MARSHALL, F., HAUDA, K.M., COUNTS, C., HURWITZ, H., SIMONS, J.W., LEVITSKY, H.I. and PARDOLL, D.M., Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J. Imumunother. Emphasis. Tumor Immunol., 18, 1-9 (1995).
12. KOO, G.C., DUMONT, F.J., TUTT, M., HACKETT, J., Jr. and KUMAR, V., The NK-1.1(-) mouse: A model to study differentiation of murine NK cells. J. Immunol., 137, 3742-3747 (1986).
13. LEVITSKY, H.I., LAZENBY, A., HAYASHI, R.J. and PARROLL, D.M., In vivo priming of two distinct antitumor effector populations: The role of MHC class I expression. J. exp. Med., 179, 1215-1224. (1994).
14. LIN, K.Y., GUARNIERI, F.G., STAVELEY, O.C.K.F., LEVITSKY, H.I., AUGUST, J.T., PARDOLL, D.M. and WU, T.C., Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res., 56, 21-26 (1996).
15. MAHVI, D.M., SONDEL, P.M., YANG, N.S., ALBERTINI, M.R., SCHILLER, J.H., HANK, J., HEINER, J., GAN, J., SWAIN, W. and LOGRONO, R., Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum. Gene Ther., 8, 875-891 (1997).
16. MORTON, D.L., FOSHAG, L.J., HOON, D.S., NIZZE, J.A., FAMATIGA, E., WANEK, L.A., CHANG, C., DAVTYAN, D.G., GUPTA, R.K., ELASHOFF, R. and IRIE, R.F., Prolongation of survival in metastatic melanoma active specific immunotherapy with a new polyvalent melanoma vaccine [published erratum appears in Ann. Surg. 1993 Mar;217(3):309]. Ann. Surg., 216, 463-482 (1992).
17. PARDOLL, D.M., Cancer vaccines. Nature (Med.), 4, 525-531 (1998).
18. PLAUTZ, G.E., YANG, Z.Y., WU, B.Y., GAO, X., HUANG, L. and NABEL, G.J., Immunotherapy of malignancy by in vivo gene transfer into tumors (see comments). Proc. nat. Acad. Sci. (Wash.), 90, 4645-4649 (1993).
19. SARMIENTO, M., GLASEBROOK, A.L. and FITCH, F.W., IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol., 125, 2665-2672 (1980).
20. SIMONS, J.W. and 18 OTHERS, Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res., 57, 1537-1546 (1997).
21. SOUBERBIELLE, B.E., WESTBY, M., GANZ, S., KAYAGA, J., MENDES, R., MORROW, W.J. and DALGLEISH, A.G., Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model. Gene Ther., 5, 1447-1454 (1998).
22. STEINMAN, R.M., The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol., 9, 271-296 (1991).
23. SZNOL, M. and HOLMLUND, J., Antigen-specific agents in development. Semin. Oncol., 24, 173-186 (1997).
24. THOMAS, M.C., GRETEN, T.F., PARDOLL, D.M. and JAFFEE, E.M., Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum. Gene Ther., 9, 835-843 (1998).
25. TOES, R.E., BLOM, R.J., VAN DER VOORT, E., OFFRINGA, R., MELIEF, C.J. and KAST, W.M., Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res., 56, 3782-3787 (1996).
26. WOODLOCK, T.J., SAHASRABUDHE, D.M., MARQUIS, D.M., GREENE, D., PANDYA, K.J. and MCCUNE, C.S., Active specific immunotherapy for metastatic colorectal carcinoma: phase 1 study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. J. Immunother., 22, 251-259 (1999).
27. WU, T.-C., GUARNIERI, F.G., STAVELEY, O.C.K.F., VISCIDI, R.P., LEVITSKY, H.I., HEDRICK, L., CHO, K.R., AUGUST, J.T. and PARDOLL, D.M., Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. nat. Acad. Sci. (Wash.), 92, 11671-11675 (1995a).
28. WU, T.-C., HUANG, A.Y.C., JAFFEE, E., LEVITSKY, H. and PARDOLL, D.M., A REASSESSMENT OF THE ROLE OF B7-1 IN ANTI-TUMOR IMMUNITY. J. EXP. Med., 182, 1415-1421. (1995b).
29. WUNDERLICH, J. and SHEARER, G., Induction and measurement of cytotoxic T lymphocyte activity. Curr. Protocols Immunol., 1, 3.11.01-3.11.15 (1994).
30. ZEHBE, I., WILANDER, E., DELIUS, H. and TOMMASINO, M., Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res., 58, 829-833 (1998).